• Kalaris Therapeutics named Laurie Keating to its board, effective Aug. 1, 2026.
• Director Morana Jovan-Embiricos will step down as Keating joins.
• Keating is chair of PepGen’s board, serves on Immuneering’s board, led legal functions at Alnylam, previously general counsel at Millennium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607061605PRIMZONEFULLFEED9756372) on July 06, 2026, and is solely responsible for the information contained therein.